COVID-19 as an acute inflammatory disease

Rose H. Manjili, Melika Zarei, Mehran Habibi, Masoud H. Manjili

Research output: Contribution to journalReview articlepeer-review

Abstract

The 2019 coronavirus disease (COVID-19) pandemic caused by the virus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has created an unprecedented global crisis for the infrastructure sectors, including economic, political, healthcare, education, and research systems. Although over 90% of infected individuals are asymptomatic or manifest noncritical symptoms and will recover from the infection, those individuals presenting with critical symptoms are in urgent need of effective treatment options. Emerging data related to mechanism of severity and potential therapies for patients presenting with severe symptoms are scattered and therefore require a comprehensive analysis to focus research on developing effective therapeutics. A critical literature review suggests that the severity of SARS-CoV-2 infection is associated with dysregulation of inflammatory immune responses, which in turn inhibits the development of protective immunity to the infection. Therefore, the use of therapeutics that modulate inflammation without compromising the adaptive immune response could be the most effective therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)12-19
Number of pages8
JournalJournal of Immunology
Volume205
Issue number1
DOIs
StatePublished - Jul 1 2020

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'COVID-19 as an acute inflammatory disease'. Together they form a unique fingerprint.

Cite this